Crossmark

Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment

Crossref DOI link: https://doi.org/10.1007/s12029-022-00840-0

Published Online: 2022-06-16

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Basso, Jeziel

Schwartsmann, Gilberto

Ibaldi, Mariana Rodrigues

Schaefer, Vitoria Daniela

Pavei, Carla Casagrande

Hahn, Roberta Zilles

Antunes, Marina Venzon

Linden, Rafael https://orcid.org/0000-0002-6966-5073
License Information

Text and Data Mining valid from 2022-06-16

Version of Record valid from 2022-06-16
More Information

Article History

Accepted: 5 June 2022

First Online: 16 June 2022

Declarations

:

: The study protocol was reviewed and approved by the institutional ethics committee. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written informed consent to participate in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below